186 related articles for article (PubMed ID: 33753107)
1. Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy.
Joharapurkar A; Patel V; Kshirsagar S; Patel MS; Savsani H; Jain M
Eur J Pharmacol; 2021 May; 899():174032. PubMed ID: 33753107
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy.
Deng G; Moran EP; Cheng R; Matlock G; Zhou K; Moran D; Chen D; Yu Q; Ma JX
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5030-5042. PubMed ID: 28979999
[TBL] [Abstract][Full Text] [Related]
3. Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Müller cells.
Lin M; Chen Y; Jin J; Hu Y; Zhou KK; Zhu M; Le YZ; Ge J; Johnson RS; Ma JX
Diabetologia; 2011 Jun; 54(6):1554-66. PubMed ID: 21360191
[TBL] [Abstract][Full Text] [Related]
4. Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway.
Makled MN; El-Kashef DH
Life Sci; 2020 Jul; 253():117729. PubMed ID: 32348836
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
6. Curcumin Attenuates Retinal Vascular Leakage by Inhibiting Calcium/Calmodulin-Dependent Protein Kinase II Activity in Streptozotocin-Induced Diabetes.
Li J; Wang P; Ying J; Chen Z; Yu S
Cell Physiol Biochem; 2016; 39(3):1196-208. PubMed ID: 27595397
[TBL] [Abstract][Full Text] [Related]
7. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
[TBL] [Abstract][Full Text] [Related]
8. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
[TBL] [Abstract][Full Text] [Related]
9. Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats.
Si YF; Wang J; Guan J; Zhou L; Sheng Y; Zhao J
Br J Pharmacol; 2013 Jun; 169(3):619-31. PubMed ID: 23488985
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity.
Kamau F; Strijdom H; Mwangi P; Blackhurst D; Imperial E; Salie R
Vascul Pharmacol; 2019 Oct; 121():106577. PubMed ID: 31284000
[TBL] [Abstract][Full Text] [Related]
11. Chlorogenic acid attenuates diabetic retinopathy by reducing VEGF expression and inhibiting VEGF-mediated retinal neoangiogenesis.
Mei X; Zhou L; Zhang T; Lu B; Sheng Y; Ji L
Vascul Pharmacol; 2018 Feb; 101():29-37. PubMed ID: 29146180
[TBL] [Abstract][Full Text] [Related]
12. An endothelin type A receptor antagonist reverses upregulated VEGF and ICAM-1 levels in streptozotocin-induced diabetic rat retina.
Masuzawa K; Goto K; Jesmin S; Maeda S; Miyauchi T; Kaji Y; Oshika T; Hori S
Curr Eye Res; 2006 Jan; 31(1):79-89. PubMed ID: 16421022
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor-A
Ved N; Hulse RP; Bestall SM; Donaldson LF; Bainbridge JW; Bates DO
Clin Sci (Lond); 2017 Jun; 131(12):1225-1243. PubMed ID: 28341661
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
Qiu F; Meng T; Chen Q; Zhou K; Shao Y; Matlock G; Ma X; Wu W; Du Y; Wang X; Deng G; Ma JX; Xu Q
Mol Pharm; 2019 May; 16(5):1958-1970. PubMed ID: 30912953
[TBL] [Abstract][Full Text] [Related]
15. Effect of antioxidant N-acetylcysteine on diabetic retinopathy and expression of VEGF and ICAM-1 from retinal blood vessels of diabetic rats.
Zhu Y; Zhang XL; Zhu BF; Ding YN
Mol Biol Rep; 2012 Apr; 39(4):3727-35. PubMed ID: 21952821
[TBL] [Abstract][Full Text] [Related]
16. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Joshi SR
Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
[TBL] [Abstract][Full Text] [Related]
17. The ethanol extract of Zingiber zerumbet rhizomes mitigates vascular lesions in the diabetic retina.
Hong TY; Tzeng TF; Liou SS; Liu IM
Vascul Pharmacol; 2016 Jan; 76():18-27. PubMed ID: 26319672
[TBL] [Abstract][Full Text] [Related]
18. Pigment epithelium-derived factor inhibits retinal microvascular dysfunction induced by 12/15-lipoxygenase-derived eicosanoids.
Ibrahim AS; Tawfik AM; Hussein KA; Elshafey S; Markand S; Rizk N; Duh EJ; Smith SB; Al-Shabrawey M
Biochim Biophys Acta; 2015 Mar; 1851(3):290-8. PubMed ID: 25562624
[TBL] [Abstract][Full Text] [Related]
19. Lactucaxanthin protects retinal pigment epithelium from hyperglycemia-regulated hypoxia/ER stress/VEGF pathway mediated angiogenesis in ARPE-19 cell and rat model.
Anitha RE; Janani R; Peethambaran D; Baskaran V
Eur J Pharmacol; 2021 May; 899():174014. PubMed ID: 33705802
[TBL] [Abstract][Full Text] [Related]
20. Α-Melanocyte-Stimulating Hormone Protects Early Diabetic Retina from Blood-Retinal Barrier Breakdown and Vascular Leakage via MC4R.
Cai S; Yang Q; Hou M; Han Q; Zhang H; Wang J; Qi C; Bo Q; Ru Y; Yang W; Gu Z; Wei R; Cao Y; Li X; Zhang Y
Cell Physiol Biochem; 2018; 45(2):505-522. PubMed ID: 29402864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
